What is Pathalys Pharma?
Pathalys Pharma, Inc. operates as a specialized, late-stage clinical biopharmaceutical entity dedicated to addressing the significant unmet medical needs associated with End-Stage Kidney Disease (ESKD). The company focuses on the research, development, and eventual delivery of innovative therapeutic solutions designed to improve patient outcomes in the management of chronic renal conditions. By maintaining a rigorous focus on clinical excellence and therapeutic efficacy, Pathalys Pharma has established itself as a high-authority player in the nephrology and life sciences sectors.
The company's market position is bolstered by a robust intellectual property portfolio and a strategic approach to drug development that prioritizes high-impact interventions. As a private enterprise, Pathalys Pharma utilizes its capital resources to bridge the gap between experimental science and clinical application, ensuring that its therapeutic candidates are optimized for regulatory approval and market entry.
How much funding has Pathalys Pharma raised?
Pathalys Pharma has raised a total of $255M across 2 funding rounds:
Debt
$150M
Series B
$105M
Debt (2023): $150M with participation from Carlyle, Abingworth, Catalys Pacific, DaVita, and OrbiMed
Series B (2024): $105M led by Samsara BioCapital, TCG Crossover, and Catalys Pacific
Key Investors in Pathalys Pharma
Samsara BioCapital
Samsara BioCapital is a venture firm focused on creating transformative therapeutics by partnering with scientists and drug developers to support the next generation of medical breakthroughs.
TCG Crossover
TCG Crossover is a science-driven investment firm that specializes in advancing disruptive medicines and supporting breakthrough therapies with the potential to transform healthcare.
Catalys Pacific
Catalys Pacific is a life sciences investment firm that creates and funds global biotech companies, with a specific focus on targeted therapies for chronic kidney disease and hypertension.
What's next for Pathalys Pharma?
Looking ahead, the strategic deployment of the $105M will likely center on the completion of pivotal clinical studies and the expansion of the company's regulatory affairs capabilities. As Pathalys Pharma transitions from a development-focused entity to a potential commercial-stage organization, the focus will shift toward scaling manufacturing processes and establishing the necessary infrastructure for market access. The continued support from top-tier life sciences investors suggests a high degree of institutional alignment regarding the company's long-term value proposition. Future milestones will likely include data readouts from ongoing trials and the initiation of pre-commercialization activities, which will be essential for the successful launch of its therapeutic pipeline in the competitive ESKD market.
See full Pathalys Pharma company page
